[Nephrotoxicity--proteinuria and hypertension--]

Area of Science:

• Oncology
• Nephrology
• Pharmacology

Background:

• Targeted and biological therapies aim to improve anticancer treatment efficacy.
• Inhibiting tumor angiogenesis, a key process in cancer development, is a targeted therapy approach.
• Anti-angiogenesis inhibitors, like bevacizumab, show promise but are associated with nephrotoxic side effects.

Purpose of the Study:

• To review the nephrotoxic side effects of bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent.
• To discuss the mechanisms behind bevacizumab-induced hypertension and proteinuria.
• To highlight the importance of monitoring and managing renal complications in patients receiving anti-VEGF therapy.

Main Methods:

• Review of scientific literature on bevacizumab and its effects on the kidney.
• Analysis of the mechanisms of VEGF inhibition and its impact on glomerular function.
• Discussion of clinical observations and management strategies for bevacizumab-induced nephrotoxicity.

Main Results:

• Bevacizumab, a monoclonal antibody targeting VEGF, is associated with significant hypertension and proteinuria.
• Mechanisms include reduced endothelial nitric oxide synthase (eNOS) activity and glomerular endothelial cell damage.
• Proteinuria may result from nephrin suppression, potentially leading to nephritic syndrome or thrombotic microangiopathy.

Conclusions:

• Anti-VEGF agents like bevacizumab necessitate regular monitoring of blood pressure and urinary protein levels.
• Patients experiencing nephrotoxicities require specialized nephrology care and appropriate antihypertensive treatment.
• Managing renal side effects is crucial for optimizing outcomes in cancer patients treated with bevacizumab.